SCHEMBL1167352

SCHEMBL1167352

CC(=O)c1ccc(Cn2ccc(NC(=O)OCc3ccc(F)cc3Cl)n2)o1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 8/20 0.46
NPSR1 Q6W5P4 6/20 0.46
HTT P42858 4/20 0.46
CYP1A2 P05177 3/20 0.46
CYP2C19 P33261 3/20 0.46
HPGD P15428 2/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2C9 P11712 1/20 0.46
LMNA P02545 5/20 0.46
GAA P10253 1/20 0.46
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
TP53 P04637 1/20 0.46
ALDH1A1 P00352 4/20 0.44
L3MBTL1 Q9Y468 2/20 0.42
POLB P06746 1/20 0.42
TSHR P16473 1/20 0.41
MAPT P10636 2/20 0.41
STAT3 P40763 1/20 0.41
CACNA1G O43497 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1166352 0.87 NPSR1 (0.49) SMN1; SMN2NPSR1HTTCYP1A2CYP2C19
SCHEMBL1167222 0.87 NPC1 (0.52) SMN1; SMN2NPSR1HTTCYP1A2CYP2C19
SCHEMBL1166780 0.86 SMN1; SMN2 (0.48) SMN1; SMN2NPSR1HTTCYP1A2CYP2C19
SCHEMBL1165912 0.85 NPSR1 (0.45) SMN1; SMN2NPSR1HTTCYP1A2CYP2C19
SCHEMBL1167178 0.85 NPSR1 (0.44) SMN1; SMN2NPSR1HTTCYP1A2CYP2C19
SCHEMBL1166275 0.84 NPSR1 (0.45) SMN1; SMN2NPSR1HTTCYP1A2CYP2C19
SCHEMBL1166624 0.84 SMN1; SMN2 (0.53) SMN1; SMN2NPSR1HTTCYP1A2CYP2C19
SCHEMBL1167247 0.83 ALDH1A1 (0.47) SMN1; SMN2NPSR1HTTCYP1A2CYP2C19
SCHEMBL1167203 0.83 LMNA (0.48) SMN1; SMN2NPSR1HTTCYP1A2CYP2C19
SCHEMBL1166172 0.83 CACNA1G (0.48) SMN1; SMN2NPSR1HTTCYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2242743-B1 AMINOPYRAZOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2013-08-21 EP claimed
US-8288419-B2 Aminopyrazole derivatives ACTELION PHARMACEUTICALS, LTD (CH) 2012-10-16 US claimed
US-20110034516-A1 AMINOPYRAZOLE DERIVATIVES ACTELION (CH) 2011-02-10 US claimed
EP-2242743-B1 AMINOPYRAZOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2013-08-21 EP disclosed
US-8288419-B2 Aminopyrazole derivatives ACTELION PHARMACEUTICALS, LTD (CH) 2012-10-16 US disclosed
US-20110034516-A1 AMINOPYRAZOLE DERIVATIVES ACTELION (CH) 2011-02-10 US disclosed
EP-2242743-A1 AMINOPYRAZOLE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-10-27 EP disclosed
WO-2009077954-A1 AMINOPYRAZOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034516-A1 AMINOPYRAZOLE DERIVATIVES CYP3A43, CYP1A2, CYP3A5 SMN1; SMN2 4612/4885NPSR1 578/4885HTT 3838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.